Related Experiment Videos
Antithrombin III concentrates.
1Plasma Derivatives Medical Services, American Red Cross National Headquarters, Washington, DC.
Hematology/Oncology Clinics of North America
|October 1, 1992
Summary
Antithrombin III (AT III) concentrates are available in the US for preventing and treating blood clots in patients with AT III deficiency. Their use in both hereditary and acquired deficiency conditions is reported.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Antithrombin III (AT III) is a critical protein in regulating blood coagulation.
- Deficiency in AT III increases the risk of thrombotic events.
- Various AT III concentrates are available for therapeutic use.
Purpose of the Study:
- To describe the characteristics of available antithrombin III concentrates in the United States.
- To summarize the efficacy of AT III concentrates in managing thrombotic episodes in hereditary AT III deficiency.
- To report on the application of AT III concentrates in acquired AT III deficiency states.
Main Methods:
- Review of available antithrombin III concentrate products in the US market.
- Summary of clinical data on the effectiveness of AT III concentrates.
- Analysis of case reports and studies on acquired AT III deficiency.
Main Results:
- General characteristics of US-available AT III concentrates are detailed.
- Evidence supports the effectiveness of AT III concentrates in preventing and treating thrombosis in hereditary AT III deficiency.
- Clinical use in acquired AT III deficiency conditions is documented.
Conclusions:
- Antithrombin III concentrates are valuable therapeutic agents for patients with AT III deficiency.
- These concentrates play a role in both hereditary and acquired deficiency states.
- Further research may elucidate optimal use in complex thrombotic conditions.